Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders

Obesity Reviews

Volumn 4, Issue 1, 2003, Pages 43-55

  Goossens, G H ^a   Blaak, E E ^a   Van Baak, M A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Angiotensin II; Blood flow; Metabolism; Obesity

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ADIPOCYTE; ADIPOSE TISSUE; AUTOCRINE EFFECT; BLOOD FLOW; ENDOCRINE FUNCTION; HYPERTENSION; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARACRINE SIGNALING; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

ADIPOSE TISSUE; ANGIOTENSIN II; ANIMALS; HUMANS; OBESITY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0037300017     PISSN: 14677881     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1467-789X.2003.00091.x     Document Type: Review

References (179)

1. Tamura K, Umemura S, Fukamizu A, Ishii M, Murakami K. Recent advances in the study of renin and angiotensinogen genes: from molecules to the whole body. Hypertens Res 1995; 18: 7-18.
2. Inagami T. A memorial to Robert Tiegerstedt: the centennial of renin discovery. Hypertension 1998; 32: 953-957.
3. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993; 43: 1-20.
4. Reid IA, Morris BJ, Ganong WF. The renin-angiotensin system. Annu Rev Physiol 1978; 40: 377-410.
5. Dorer FE, Kahn JR, Lentz KE, Levine M, Skeggs LT, Purification and properties of angiotensin-converting enzyme from hog lung, Circ Res 1972; 31: 356-366.
6. Skeggs LT, Lentz KE, Gould AB, Hochstrasser H, Kahn JR, Biochemistry and kinetics of the renin-angiotensin system. Fed Proc 1967; 26: 42-47.
7. Turner AJ, Hooper NM, The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002; 23; 177-183.
8. Hollenberg NK, Fisher ND, Price DA, Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-392,
9. Shiota N, Okunishi H, Takai S, Mikoshiba I, Sakonjo H, Shibata N, Miyazaki M. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery, Circulation 1999; 99: 1084-1090.
10. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W, Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80: 219-227.
11. Urata H, Nishimura H, Ganten D, Chymase-dependent angiotensin II forming systems in humans, Am J Hypertens 1996; 9: 277-284.
12. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-1281.
13. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
14. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 163: 284-291.
15. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR, Johnson AL, Timmermans PBMWM. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 165: 196-203.
16. Chaki S, Inagami T. Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. Biochem Biophys Res Commun 1992; 182: 388-394.
17. Swanson GN, Hanesworth JM, Sardinia MF, Coleman JK, Wright JW, Hall KL, Miller-Wing AV, Stobb JW, Cook VI, Harding EC et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992; 40: 409-419.
18. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Hohle S, Meffert S, Stoll M, Stroth U, Zhu YZ. Angiotensin receptors. J Hypertens 1996; 14: S95-S103.
19. Brown L, Sernia C. Angiotensin receptors in cardiovascular diseases. Clin Exp Pharmacol Physiol 1994; 21: 811-818.
20. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998; 83: 1182-1191.
21. Inagami T. Recent progress in molecular and cell biological studies of angiotensin receptors. Curr Opin Nephrol Hypertens 1995; 4: 47-54.
22. de Gasparo M, Husain A, Alexander W, Catt KJ, Chiu AT, Drew M, Goodfriend T, Harding JW, Inagami T, Timmermans PB. Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 25: 924-927,
23. Iwai N, Inagami T. Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 1992; 298: 257-260.
24. Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. Am J Hypertens 2000; 13: 31S-38S.
25. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270-1277.
26. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
27. English V, Cassis L. Facilitation of sympathetic neurotransmission contributes to angiotensin regulation of body weight. J Neural Transm 1999; 106: 631-644.
28. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000; 35: 193-201.
29. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000; 58: 251-259.
30. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
31. Chung O, Stoll M, Unger T. Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Press 1996; 2: 47-52.
32. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92: 10663-10667.
33. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 101: 2206-2212.
34. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
35. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
36. Berry C, Touyz R, Dominiczak AF, Webb RC, Johns DG. Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001; 281: H2337-H2365.
37. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639-672.
38. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993; 268: 24539-24542.
39. Zhang J, Pratt RE. The AT2 receptor selectively associates with Gialpha2 and Gialpha3 in the rat fetus. J Biol Chem 1996; 271:15026-15033.
40. Hayashida W, Horiuchi M, Dzau VJ. Intracellular third loop domain of angiotensin II type-2 receptor. Role in mediating signal transduction and cellular function. J Biol Chem 1996; 271: 21985-21992.
41. Buisson B, Laflamme L, Bottari SP, de Gasparo M, Gallo-Payet N, Payer MD. A G protein is involved in the angiotensin AT2 receptor inhibition of the T-type calcium current in nondifferentiated NG108-15 cells. J Biol Chem 1995; 270: 1670-1674.
42. Shanmugam S, Corvol P, Gasc JM. Angiotensin II type 2 receptor mRNA expression in the developing cardiopulmonary system of the rat. Hypertension 1996; 28: 91-97.
43. Siragy HM. The role of the AT2 receptor in hypertension. Am J Hypertens 2000; 13: 62S-67S.
44. Gallinat S, Busche S, Raizada MK, Sumners C. The angiotensin II type 2 receptor: an enigma with multiple variations. Am J Physiol Endocrinol Metab 2000; 278: E357-E374.
45. Horiuchi M, Lehtonen JY, Daviet L. Signaling mechanism of the AT2 angiotensin II receptor: crosstalk between AT1 and AT2 receptors in cell growth. Trends Endocrinol Metab 1999; 10: 391-396.
46. Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens 1999; 17: 1775-1786.
47. Horiuchi M, Yamada T, Hayashida W, Dzau VJ. Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis. J Biol Chem 1997; 272: 11952-11958.
48. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997; 272: 19022-19026.
49. Riordan JF. Angiotensin II: biosynthesis, molecular recognition, and signal transduction. Cell Mol Neurobiol 1995; 15: 637-651.
50. Chai SY, Zhuo J, Mendelsohn FA. Localization of components of the renin-angiotensin system and site of action of inhibitors. Arzneimittelforschung 1993; 43: 214-221.
51. Dostal DE, Rothblum KN, Chernin MI, Cooper GR, Baker KM. Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. Am J Physiol 1992; 263: C838-C850.
52. Mulrow PJ. Adrenal renin: regulation and function. Front Neuroendocrinol 1992; 13: 47-60.
53. Dzau VJ, Ellison KE, Brody T, Ingelfinger J, Pratt RE. A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology 1987; 120: 2334-2338.
54. Murakami E, Eggena P, Barrett JD, Sambhi MP. Heterogeneity of renin substrate released from hepatocytes and in brain extracts. Life Sci 1984; 34: 385-392.
55. Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest 1993; 91: 2058-2064.
56. Schling P, Mallow H, Trindl A, Loffler G. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord 1999; 23: 336-341.
57. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998; 83: 3925-3929.
58. Jones BH, Standridge MK, Taylor JW, Moustaid N. Angiotensinogen gene expression in adipose tissue, analysis of obese models and hormonal and nutritional control. Am J Physiol 1997; 273: R236-R242.
59. Jonsson JR, Game PA, Head RJ, Frewin DB. The expression and localisation of the angiotensin-converting enzyme mRNA in human adipose tissue. Blood Press 1994; 3: 72-75.
60. Crandall DL, Herzlinger HE, Saunders BD, Zolotor RC, Feliciano L, Cervoni P. Identification and characterization of angiotensin II receptors in rat epididymal adipocyte membranes. Metabolism 1993; 42: 511-515.
61. Cassis LA, Saye J, Peach MJ. Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988; 11: 591-596.
62. Danser AH. Local renin-angiotensin systems. Mol Cell Biochem 1996; 157: 211-216.
63. Unger T, Gohlke P. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors. Am J Cardiol 1990; 65: 31-101.
64. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988; 77: 14-113.
65. Cooper R, Forrester T, Ogunbiyi O, Muffinda J. Angiotensinogen levels and obesity in four black populations. ICSHIB Investigators. J Hypertens 1998; 16: 571-575.
66. Cooper R, McFarlane-Anderson N, Bennett FI, Wilks R, Puras A, Tewksbury D, Ward R, Forrester T. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 1997; 11: 107-111.
67. Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M, Ishigami T, Yabana M, Kihara M, Inoue S, Ishii M. Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997; 10: 629-633.
68. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 1995; 95:948-953.
69. Licata G, Scaglione R, Ganguzza A, Corrao S, Donatelli M, Parrinello G, Dichiara MA, Merlino G, Cecala MG. Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. Am J Hypertens 1994; 7: 314-320.
70. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994; 7: 886-893.
71. van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 2000; 8: 337-341.
72. van Harmelen V, Elizalde M, Ariapart P, Bergstedt-Lindqvist S, Reynisdottir S, Hoffstedt J, Lundkvist I, Bringman S, Arner P. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int J Obes Relat Metab Disord 2000; 24: 673-678.
73. Giacchetti G, Faloia E, Sardu C, Camilloni MA, Mariniello B, Gatti C, Garrapa GG, Guerrieri M, Mantero F. Gene expression of angiotensinogen in adipose tissue of obese patients. Int J Obes Relat Metab Disord 2000; 24: S142-S143.
74. Hainault I, Nebout G, Turban S, Ardouin B, Ferre P, Quignard-Boulange A. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol Endocrinol Metab 2002; 282: E59-E66.
75. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-2729.
76. Sjostrom CD, Lissner L, Sjostrom L. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Swedish Obese Subjects. Obes Res 1997; 5: 519-530.
77. Alonso-Galicia M, Brands MW, Zappe DH, Hall JE. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 1996; 28: 1047-1054.
78. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19: 339-344.
79. Safonova I, Aubert J, Negrel R, Ailhaud G. Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Biochem J 1997; 322: 235-239.
80. Aubert J, Safonova I, Negrel R, Ailhaud G. Insulin downregulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells. Biochem Biophys Res Commun 1998; 250: 77-82.
81. Dostal DE, Booz GW, Baker KM. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and beta-adrenergic stimulation. Basic Res Cardiol 2000; 95: 485-490.
82. Jikihara H, Handwerger S, Poisner AM. Beta-adrenergic regulation of renin expression in differentiated U-937 monocytic cells. Biochem Pharmacol 1997; 53: 1883-1888.
83. Hsueh WA, Goldstone R, Carlson EJ, Horton R. Evidence that the beta-adrenergic system and prostaglandins stimulate renin release through different mechanisms. J Clin Endocrinol Metab 1985; 61: 399-403.
84. Pettinger WA, Mitchell HC. Renin release, saralasin and the vasodilator-beta-blocker drug interaction in man. N Engl J Med 1975; 292: 1214-1217.
85. Ramsay DJ. Beta-adrenergic thirst and its relation to the renin-angiotensin system. Fed Proc 1978; 37: 2689-2693.
86. Sinaiko AR. Influence of adrenergic nervous and prostaglandin systems on hydralazine-induced renin release. Life Sci 1983; 33:2269-2275.
87. Ueda H. Renin and nervous system. Jpn Heart J 1976; 17: 521-526.
88. Zayas VM, Blumenfeld JD, Bading B, McDonald M, James GD, Lin YF, Sharrock NE, Sealey JE, Laragh JH. Adrenergic regulation of renin secretion and renal hemodynamics during deliberate hypotension in humans. Am J Physiol 1993; 265: F686-F692.
89. Nakamaru M, Jackson EK, Inagami T. Role of vascular angiotensin II released by beta-adrenergic stimulation in rats. J Cardiovasc Pharmacol 1986; 8: S1-S5.
90. Pratt JH, McAteer JA. Beta-adrenergic enhancement of angiotensin II-stimulated aldosterone secretion. Life Sci 1989; 44: 2089-2095.
91. Sil P, Sen S. Angiotensin II and myocyte growth: role of fibroblasts. Hypertension 1997; 30: 209-216.
92. Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint-Marc P, Teboul M. Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Relat Metab Disord 2000; 24: S33-S35.
93. Crandall DL, Armellino DC, Busler DE, McHendry-Rinde B, Kral JG. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 1999; 140: 154-158.
94. Lyle RE, Habener JF, McGehee RE Jr. Antisense oligonucleotides to differentiation-specific element binding protein (DSEB) mRNA inhibit adipocyte differentiation. Biochem Biophys Res Commun 1996; 228: 709-715.
95. Darimont C, Vassaux G, Ailhaud G, Negrel R. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 1994; 135: 2030-2036.
96. Richelsen B. Prostaglandins in adipose tissue - with special reference to triglyceride metabolism. Dan Med Bull 1991; 38: 228-244.
97. Hyman BT, Stoll LL, Spector AA. Prostaglandin production by 3T3-L1 cells in culture. Biochim Biophys Acta 1982; 713: 375-385.
98. Negrel R, Ailhaud G. Metabolism of arachidonic acid and prostaglandin synthesis in the preadipocyte clonal line ob17. Biochem Biophys Res Commun 1981; 98: 768-777.
99. Negrel R. Prostacyclin as a critical prostanoid in adipogenesis. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 383-386.
100. Vassaux G, Gaillard D, Ailhaud G, Negrel R. Prostacyclin is a specific effector of adipose cell differentiation. Its dual role as a cAMP- and Ca(2+)-elevating agent. J Biol Chem 1992; 267: 11092-11097.
101. Catalioto RM, Gaillard D, Maclouf J, Ailhaud G, Negrel R. Autocrine control of adipose cell differentiation by prostacyclin and PGF2 alpha. Biochim Biophys Acta 1991; 1091: 364-369.
102. Gaillard D, Negrel R, Lagarde M, Ailhaud G. Requirement and role of arachidonic acid in the differentiation of pre-adipose cells. Biochem J 1989; 257: 389-397.
103. Negrel R, Gaillard D, Ailhaud G. Prostacyclin as a potent effector of adipose-cell differentiation. Biochem J 1989; 257: 399-405.
104. Axelrod L, Minnich AK, Ryan CA. Stimulation of prostacyclin production in isolated rat adipocytes by angiotensin II, vasopressin, and bradykinin: evidence for two separate mechanisms of prostaglandin synthesis. Endocrinology 1985; 116: 2548-2553.
105. Darimont C, Vassaux G, Gaillard D, Ailhaud G, Negrel R. In situ microdialysis of prostaglandins in adipose tissue: stimulation of prostacyclin release by angiotensin II. Int J Obes Relat Metab Disord 1994; 18: 783-788.
106. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138: 1512-1519.
107. Kim S, Dugail I, Standridge M, Claycombe K, Chun J, Moustaid-Moussa N. Angiotensin II-responsive element is the insulin-responsive element in the adipocyte fatty acid synthase gene: role of adipocyte determination and differentiation factor 1/ sterol-regulatory-element-binding protein 1c. Biochem J 2001; 357: 899-904.
108. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699-1707.
109. Schling P, Loffler G. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes. Horm Metab Res 2001; 33: 189-195.
110. Boschmann M, Ringel J, Klaus S, Sharma AM. Metabolic and hemodynamic response of adipose tissue to angiotensin II. Obes Res 2001; 9: 486-491.
111. Lönnroth P, Smith U. Intermediary metabolism with an emphasis on lipid metabolism, adipose tissue, and fat cell metabolism: a review. In: Björntorp P, Brodoff BN (eds). Obesity. JB Lippincott Co: Philadelphia, 1992, pp 3-14.
112. Blaak EE. Lipolysis in adipose tissue and skeletal muscle: what to be learned from stable isotopes. Int J Obes Relat Metab Disord 2002; 26: S227 (Abstract).
113. Samra JS, Clark ML, Humpreys SM, Bannister PA, Summers LKM, Macdonald IA, Frayn KN. Evidence for glycerol uptake by adipose tissue. Proc Nutrition Soc 1999; 58: 164A.
114. Blaak EE, van Baak MA, Kemerink GJ, Pakbiers MT, Heidendal GA, Saris WH. Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects. Metabolism 1995; 44: 183-187.
115. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med 1995; 27: 435-438.
116. Leibel RL, Edens NK, Fried SK. Physiologic basis for the control of body fat distribution in humans. Annu Rev Nutr 1989; 9: 417-443.
117. Townsend RR. The effects of angiotensin-II on lipolysis in humans. Metabolism 2001; 50: 468-472.
118. Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P, Fukamizu A, Negrel R, Ailhaud G, Teboul M. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001; 142: 5220-5225.
119. Setoguchi Y, Ohnuki T, Rashid M, Nakamura T, Hattori K, Nagatomo T, Watanabe K, Mitomi A, Nakazawa M. Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats: comparison with quinapril. Pharmacology 2002; 64: 71-75.
120. Campbell DJ, Duncan AM, Kladis A, Harrap SB. Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995; 26: 426-436.
121. McGrath BP, Matthews PG, Louis W, Howes L, Whitworth JA, Kincaid-Smith PS, Fraser I, Scheinkestel C, MacDonald G, Rallings M. Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1990; 16: 831-838.
122. Enalapril in Hypertension Study Group (UK). Enalapril in essential hypertension: a comparative study with propranolol. Br J Clin Pharmacol 1984; 18: 51-56.
123. Harrison-Bernard LM, El-Dahr SS, O'Leary DF, Navar LG. Regulation of angiotensin II type 1 receptor mRNA and protein in angiotensin II-induced hypertension. Hypertension 1999; 33: 340-346.
124. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA. Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol 1998; 274: E867-E876.
125. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996; 97: 2509-2516.
126. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100: 2158-2169.
127. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996; 93: 12490-12495.
128. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884-890.
129. Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism 1996; 45: 535-541.
130. Henriksen EJ, Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 1995; 44: 267-272.
131. Vuorinen-Markkola H, Yki-Jarvinen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 1995; 44: 85-89.
132. Torlone E, Britta M, Rambotti AM, Perriello G, Santeusanio F, Brunetti P, Bolli GB. Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care 1993; 16: 1347-1355.
133. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992; 6: 175-179.
134. Torlone E, Rambotti AM, Perriello G, Botta G, Santeusanio F, Brunetti P, Bolli GB. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991; 34: 119-125.
135. Pollare T. Insulin sensitivity and blood lipids during antihypertensive treatment with special reference to ACE inhibition. J Diabet Complications 1990; 4: 75-78.
136. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1987; 17: 448-454.
137. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
138. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
139. Raccah D, Pettenuzzo-Mollo M, Provendier O, Boucher L, Cozic JA, Gorlier R, Huin P, Sicard J, Vague P. Comparison of the effects of captopril and nicardipine on insulin sensitivity and thrombotic profile in patients with hypertension and android obesity. CaptISM Study Group. Captopril Insulin Sensitivity Multicenter Study Group. Am J Hypertens 1994; 7: 731-738.
140. Shieh SM, Sheu WH, Shen DD, Fuh MM, Jeng CY, Jeng JR, Chen YD, Reaven GM. Improvement in metabolic risk factors for coronary heart disease associated with cilazapril treatment. Am J Hypertens 1992; 5: 506-510.
141. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
142. Waeber B, Brunner HR. Cardiovascular hypertrophy: role of angiotensin II and bradykinin. J Cardiovasc Pharmacol 1996; 27: S36-S40.
143. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
144. Isami S, Kishikawa H, Araki E, Uehara M, Kaneko K, Shirotani T, Todaka M, Ura S, Motoyoshi S, Matsumoto K, Miyamura N, Shichiri M. Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway. Diabetologia 1996; 39: 412-420.
145. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schmit MB, Dietze GJ. ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 1999; 277: R332-R336.
146. Miyata T, Taguchi T, Uehara M, Isami S, Kishikawa H, Kaneko K, Araki E, Shichiri M. Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts. Eur J Endocrinol 1998; 138: 344-352.
147. Coimbra CC, Garofalo MA, Foscolo DR, Xavier AR, Migliorini RH. Gluconeogenesis activation after intravenous angiotensin II in freely moving rats. Peptides 1999; 20: 823-827.
148. Whitton PD, Rodrigues LM, Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J 1978; 176: 893-898.
149. DeWitt LM, Putney JW Jr. Stimulation of glycogenolysis in hepatocytes by angiotensin II may involve both calcium release and calcium influx. FEBS Lett 1983; 160: 259-263.
150. Hems DA, Rodrigues LM, Whitton PD. Glycogen phosphorylase, glucose output and vasoconstriction in the perfused rat liver. Concentration -dependence of actions of adrenaline, vasopressin and angiotensin II. Biochem J 1976; 160: 367-374.
151. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
152. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
153. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
154. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
155. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
156. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
157. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-1935.
158. Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens Suppl 1994; 12: S31-S35.
159. Abassi ZA, Kelly G, Golomb E, Klein H, Keiser HR. Losartan improves the natriuretic response to ANF in rats with high-output heart failure. J Pharmacol Exp Ther 1994; 268: 224-230.
160. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-1609.
161. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-935.
162. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-1118.
163. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-1292.
164. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31: 349-355.
165. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999; 33: 1237-1242.
166. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995; 26: 233-240.
167. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
168. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999; 33: 613-621.
169. Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 1999; 34: 1112-1116.
170. Gigante B, Piras O, De Paolis P, Porcellini A, Natale A, Volpe M. Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens 1998; 16: 2039-2043.
171. Goto M, Mukoyama M, Suga S, Matsumoto T, Nakagawa M, Ishibashi R, Kasahara M, Sugawara A, Tanaka I, Nakao K. Growth-dependent induction of angiotensin II type 2 receptor in rat mesangial cells. Hypertension 1997; 30: 358-362.
172. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 1996; 27: 760-765.
173. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-657.
174. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377: 744-747.
175. Schuijt MP, de Vries R, Saxena PR, Danser AH. No vasoactive role of the angiotensin II type 2 receptor in normotensive Wistar rats. J Hypertens 1999; 17: 1879-1884.
176. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98: 2765-2773.
177. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, Poitevin P, Samuel JL. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98: 418-425.
178. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29: 634-640.
179. Menard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997; 96: 3072-3078.